Citations

Clear

9383 citation(s) found for "Thomas, PS".

Minimal clinical impact of embolization to new territory on outcomes in medium vessel occlusion strokes treated with mechanical thrombectomy: a retrospective multicenter study
Salim, Hamza , Yedavalli, Vivek , Lakhani, Dhairya A. , Milhem, Fathi , Musmar, Basel , Adeeb, Nimer , Faizy, Tobias D. , Daraghma, Motaz , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Grewal, Inayat , Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Puri, Ajit S., Dyzmann, Christian , Filipe, João Pedro , Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Jabbour, Pascal , Biswas, Arundhati , Clarençon, Frédéric, Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Salim, Hamza , Ghozy, Sherief , Scarcia, Luca , Yeo, Leonard Ll , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Colasurdo, Marco , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Siegler, James E , Nguyen, Thanh N , Essibayi, Muhammed Amir , Altschul, David J , Gonzalez, Nestor R , Hecker, Constantin , Marnat, Gaultier , Shaikh, Hamza A , Griessenauer, Christoph J , Liebeskind, David S. , Alexandre, Andrea M , Kalsoum, Erwah , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A , Heit, Jeremy J , Musmar, Basel , Regenhardt, Robert W , Lakhani, Dhairya , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Clarençon, Frédéric , Siegler, James E. , Nguyen, Thanh N. , Essibayi, Muhammed Amir , Gory, Benjamin , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Wintermark, Max , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | March 5, 2025 | Volume: 18 | Issue: 1 | Pages: 186-194

10.1136/jnis-2024-022570 | PMID 40044412 Get It

Background Mechanical thrombectomy (MT) is established as an effective treatment for large vessel occlusion strokes, but its efficacy and safety for medium vessel occlusions (MeVOs) remain less clear. This study examines the impact of periprocedural embolization to a new vascular territory (ENT) on clinical outcomes in patients with MeVO stroke treated with MT. Methods A multicenter, retrospective analysis was conducted using the MAD-MT (Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy) registry, including 2122 patients with MeVO stroke w­ho underwent MT between September 2017 and July 2023. ENT was defined as filling defects in previously unaffected territories, excluding embolization near the original occlusion, observed on final angiographic runs after retrieval of the primary thrombus. The associations between ENT, procedural variables, and 90-day clinical outcomes were evaluated, including functional independence (modified Rankin Scale (mRS) scores of 0–2), excellent outcomes (mRS 0–1), mortality, and hemorrhagic complications. Results ENT occurred in 2.9% (63/2122) of patients. Longer onset-to-arterial puncture time (adjusted OR 1.03; 95% CI 1.01 to 1.05; P=0.002) and a greater number of passes (adjusted OR 1.15; 95% CI 1.01 to 1.32; P=0.032) were associated with increased ENT risk, while excellent recanalization (thrombolysis in cerebral infarction (TICI) scale score 2c–3) was associated with reduced ENT risk (adjusted OR 0.41; 95% CI 0.23 to 0.72; P=0.002). ENT was not associated with poorer functional independence, mortality, or hemorrhagic complications. Conclusions ENT during MT for MeVO stroke occurs infrequently and does not significantly affect the clinical outcomes. These findings suggest ENT risk should not deter clinicians from performing MT in patients with MeVO. Further prospective studies are needed to validate these results.
Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer
Habib, Joseph R. , Tan, Po Hong, Miller, Max , Pellegrini, Riccardo , Andel, P. , Lafaro, Kelly J. , Hewitt, D. Brock , Morgan, Katherine A. , Busch, O.R., Molenaar, I. Quintus , Büchler, Markus W., Wolfgang, Christopher L. , Loos, Martin , Miller, Richard M., Ven Fong, Zhi, Miller, Richard Max , Rompen, Ingmar Florin , Javed, Ammar A. , Campbell, Brady A. , Kinny‐Köster, Benedict , Marchetti, Alessio , Perri, Giampaolo , Kaiser, Jörg , Daamen, Lois A. , Hank, Thomas P. , Sacks, Greg D. , Billeter, Adrian T. , Müller-Stich, Beat Peter , Marchegiani, Giovanni , Fong, Zhi Ven , Besselink, Marc G , He, Jing

Mayo Clinic

Annals of Surgery | March 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006687 | PMID 40042799 Get It

Summary of Background Data: Intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic cancer is typically managed like pancreatic intraepithelial neoplasia (PanIN)-derived pancreatic cancer. However, in IPMN-derived pancreatic cancer, the role of chemotherapy remains controversial, particularly in the neoadjuvant setting (NAT). Objective: To evaluate the role of neoadjuvant chemotherapy in IPMN-derived pancreatic cancer. Methods: Patients with IPMN-derived pancreatic cancer treated with either upfront surgery (US) or NAT were identified from eight international centers (2000-2023). Clinicopathologic data were compared. Date of first treatment was used for Kaplan-Meier and log-rank tests to compare overall (OS) and recurrence free survival (RFS). Multivariable Cox-regression was performed in patients that underwent NAT. Results: In 1,019 patients, 76 (7%) underwent NAT. Patients who received NAT had higher baseline CA19-9 levels (P<0.001). Of these 76 patients, 27 (36%), 20 (26%), and 29 (38%) had resectable, borderline resectable, or locally advanced pancreatic cancer at diagnosis, respectively. Advanced resectability stage was significantly more common in the NAT patients as compared to those who underwent US (P<0.001). OS for US patients was 38.0 months (95%CI: 33.7.1-44.3), which was not statistically different than those that received NAT [27.5 mo (95%CI: 23.1-46.7), P=0.121]. This was also valid for patients with resectable disease [US: 38.1 mo vs. NAT: 35.6 mo, P=0.920)]. Complete or marked pathological treatment response (P=0.046) and serological CA19-9 normalization after NAT (P=0.017) were associated with improved survival. On Cox-regression for OS, N2 disease [HR: 4.15 (95%CI: 1.71-10.10)], elevated CA19-9 [HR: 2.02 (95%CI:1.06-3.85)] and R1 margin [HR: 2.36 (95%CI:1.20-4.61)] was independently associated with OS after NAT, while resectability status was not. Conclusion: After NAT and resection, advanced resectability stage was not associated with worse OS indicating the value of this approach for borderline resectable and locally advanced IPMN-derived pancreatic cancer. The benefit of NAT in resectable disease is unclear and may require an individualized approach. Biological treatment effect can be assessed with CA19-9 and confirmed by pathologic response.
Time-restricted eating and autosomal dominant polycystic kidney disease: a pilot, randomized clinical trial
Steele, Cortney , Ostrow, Anna, Coleman, Erin R., George, Diana, Bing, Kristen , Ramanathan, Sumana, Gregory, Adriana , Kline, Timothy L. , Thomas, Elizabeth A. , Chonchol, Michel , Nowak, Kristen L. , Nowak, Kristen L , Wang, Wei Qiang , Gitomer, Berenice Y , Thomas, Elizabeth

Mayo Clinic

Clinical Kidney Journal | March 5, 2025 | Volume: 18 | Issue: 4 | Pages: No page available

10.1093/ckj/sfaf069 | PMID 40207097 Get It

ABSTRACT Background Autosomal dominant polycystic kidney disease (ADPKD) is the most commonly inherited progressive kidney disease. Time-restricted eating (TRE) is a fasting regimen that restricts eating to a particular window (typically 8 hours/day), which could slow cyst growth based on preclinical models. Methods A 12-month, randomized, controlled, behavioral dietary intervention compared TRE with a control group given healthy eating advice without TRE (HE), without caloric restriction. Participants underwent baseline and 12-month measurements, including adherence (percentage of participants adhering to the 8-hour window; primary outcome), and MRI to determine height-adjusted total kidney volume (htTKV) and adiposity. Results Twenty-nine participants (23 females, mean standard ± deviation 48 ± 9 years) with a body mass index of 31.1±5 kg/m2 were randomized to TRE (n = 14) or HE (n = 15). Of the total participants, 71% (n = 10) of TRE and 87% (n = 13) of HE participants completed the intervention. The eating window was 9.6 ± 3.6 hours for TRE (60% achieving the 8-hour window) and 12.0 ± 2.0 for HE groups (P = .07). At month 12, both groups lost modest weight (−2.4 ± 6.4% and −3.6 ± 5.4% in the TRE and HE groups, respectively). Annual change in htTKV was 3.0 ± 8.5% and 4.6 ± 8.8% in the TRE and HE groups, respectively. Both change in weight (r = 0.67, P &lt; .01) and change in visceral adiposity (r = 0.54, P &lt; .01) were positively correlated with change in htTKV. Conclusion Both the TRE and HE group lost modest weight at 12 months. The targeted TRE adherence of ≥75% of participants was not achieved. Weight and adiposity loss may be more important drivers of kidney growth than the timing of eating.
Cardiovascular screening and long-term outcomes in aircraft pilots
Elkhatib, Wiaam , Flipse, Thomas R, Allison, Thomas G. , Speicher, Leigh L. , Sledge, Hanna J., Li, Z. , Shapiro, Brian P. , Gharacholou, S. Michael , Li, Zhuo , Elkhatib, Wiaam Y , Gharacholou, Shahyar M, Li, Zhuo

Mayo Clinic

Heart | March 4, 2025 | Volume: 111 | Issue: 14 | Pages: 679-685

10.1136/heartjnl-2024-325243 | PMID 40037767 Get It

Background Pilots face significant occupational risks affecting cardiometabolic health and are subject to regulatory health screenings. Cardiometabolic risk factors, cardiac screening findings and outcomes among pilots have not been well reported. Objectives This study aimed to investigate cardiac evaluations of asymptomatic aircraft pilots and the association between clinical risk factors and outcomes. Methods Asymptomatic aircraft pilots referred for cardiac assessment between January 1991 and May 2023 were studied. Baseline characteristics, cardiac test findings and outcomes were evaluated. Major adverse clinical event (MACE) was defined as death, myocardial infarction, stroke, major arrhythmia, heart failure event or cardiac-related hospitalisation and estimated using Kaplan-Meier methods. Significant valvular disease by echocardiography was defined as stenosis, regurgitation or prolapse of moderate severity or greater. Aortic dilation by transthoracic echocardiogram (TTE) was defined as measuring ≥40 mm in diameter. Results 212 pilots met eligibility criteria for the study. The majority were white (92.9%) and male (91%) with a mean age of 58.5±10.9 years. Mean body mass index was 27.8±4.8 with comorbid hyperlipidaemia (48%), hypertension (32%), prior cancer (27%), sleep apnoea (15%), arrhythmia (12%) and known coronary artery disease (6%). Imaging revealed significant valvular disease (2.4%) and dilated aortas (16%) based on TTEs. Functional cardiac testing performed showed mean functional aerobic capacity of 109±24.6% reaching 11.89±2.65 metabolic equivalents with <8% showing positive findings per EKG or wall motion abnormalities on exercise TTE. Six patients received coronary angiography based on clinical evaluation, with two undergoing percutaneous coronary intervention. Over a 32-year period with a median (range) follow-up of 5.15 (0.1, 31.82) years, MACE incidence was 15%. Conclusions Asymptomatic aircraft pilots have underlying cardiovascular risk factors but good overall functional capacity, long-term outcomes and life expectancy. Prevalence of cardiac structural findings like aortic dilatation warrants increased attention during examination of these patients.
Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease
Coughlan, Gillian , Klinger, Hannah M , Boyle, Rory , Binette, Alexa Pichet , Christenson, Luke R., Chadwick, Trevor, Healy, Brian C. , Jonaitis, Erin M. , Jack, Clifford R. , Johnson, Keith A. , Langhough, Rebecca E., Properzi, Michael J , Seto, Mabel , Johnson, Sterling C., Shirzadi, Zahra , Yau, Wai‐Ying Wendy , Initiative, Alzheimer’s Disease Neuroimaging, Hurko, Orest, Black, Sanra E, Doody, Rachelle S., Doraiswamy, Murali, Gamst, Anthony, Scharre, Doug, Sperling, Reisa, Weiner, Michael W. , Green, Robert C, Christenson, Luke, Jack, Clifford R , Pichet Binette, Alexa , Betthauser, Tobey J. , Hansson, Oskar , Harrison, Theresa M. , Jacobs, Heidi I.L. , Hanseeuw, Bernard , Rentz, Dorene M. , Schultz, Aaron P. , Smith, Ruben , Johnson, Sterling C. , Mielke, Michelle M. , Manson, JoAnn E. , Sperling, Reisa Anne , Vemuri, Prashanthi , Buckley, Rachel F. , Initiative, Alzheimer’s Disease Neuroimaging, Black, Sanra E, Kaye, Jeffrey , Obisesan, Thomas O. , Rusinek, Henry

Mayo Clinic

JAMA Neurology | March 3, 2025 | Volume: 82 | Issue: 4 | Pages: 364

10.1001/jamaneurol.2025.0013 | PMID 40029638 Get It

Importance Alzheimer disease (AD) predominates in females at almost twice the rate relative to males. Mounting evidence in adults without AD indicates that females exhibit higher tau deposition than age-matched males, particularly in the setting of elevated β-amyloid (Aβ), but the evidence for sex differences in tau accumulation rates is inconclusive. Objective To examine whether female sex is associated with faster tau accumulation in the setting of high Aβ (as measured with positron emission tomography [PET]) and the moderating influence of sex on the association between APOE ε4 carrier status and tau accumulation. Data Sources This meta-analysis used data from 6 longitudinal aging and AD studies, including the Alzheimer’s Disease Neuroimaging Initiative, Berkeley Aging Cohort Study, BioFINDER 1, Harvard Aging Brain Study, Mayo Clinic Study of Aging, and Wisconsin Registry for Alzheimer Prevention. Longitudinal data were collected between November 2004 and May 2022. Study Selection Included studies required available longitudinal [ 18 F]flortaucipir or [ 18 F]-MK-6240 tau-PET scans, as well as baseline [ 11 C] Pittsburgh Compound B, [ 18 F]flutemetamol or [ 18 F]florbetapir Aβ-PET scans. Recruitment criteria varied across studies. Analyses began on August 7, 2023, and were completed on February 5, 2024. Data Extraction and Synthesis In each study, primary analyses extracted estimates for the sex (female or male) and the sex by baseline Aβ-PET status (high or low) association with longitudinal tau-PET using a series of mixed-effects models. Secondary mixed-effects models extracted the interaction estimate for the association of sex by APOE ε4 carrier status with longitudinal tau-PET. Study-specific estimates for each mixed-effects model were then pooled in a meta-analysis, and the global fixed effect (β) and total heterogeneity ( I 2 ) across studies were estimated. This study is reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Main Outcomes and Measures Seven tau-PET outcomes that showed cross-sectional sex differences were examined across temporal, parietal, and occipital lobes. Results Among 6 studies assessed, there were 1376 participants (761 [55%] female; mean [range] age at first tau scan, 71.9 [46-93] years; 401 participants [29%] with high baseline Aβ; 412 APOE ε4 carriers [30%]). Among individuals with high baseline Aβ, female sex was associated with faster tau accumulation localized to inferior temporal (β = −0.14; 95% CI, −0.22 to −0.06; P = .009) temporal fusiform (β = −0.13; 95% CI, −0.23 to −0.04; P = .02), and lateral occipital regions (β = −0.15; 95% CI, −0.24 to −0.06; P = .009) compared with male sex. Among APOE ε4 carriers, female sex was associated with faster inferior-temporal tau accumulation (β = −0.10; 95% CI, −0.16 to −0.03; P = .01). Conclusions and Relevance These findings suggest that sex differences in the pathological progression of AD call for sex-specific timing considerations when administrating anti-Aβ and anti-tau treatments.
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations
Storandt, Michael H. , Shi, Qian , Lieu, Christopher H. , George, Thomas J. , Stoppler, Melissa C. , Mauer, Elizabeth , Teslow, Emily A. , Mahipal, Amit , Jin, Zhaohui , Lieu, Christopher , George, Thomas J , Teslow, Emily A , Mahipal, Amit , Jin, Zhaohui , Shi, Qian , Eng, Cathy , Yilma, Binyam , Fragkogianni, Stamatina

Mayo Clinic

Cancers | February 28, 2025 | Volume: 17 | Issue: 5 | Pages: 836

10.3390/cancers17050836 | PMID 40075683 Get It

Background: Rates of early-onset colorectal cancer (eoCRC), defined as disease diagnosed at <50 years of age, are increasing. The incidence and spectrum of somatic and pathogenic germline variants (PGV) in this population are not well understood. Methods: This cross-sectional study leveraged Tempus’ clinicogenomic database, including de-identified records of patients diagnosed with CRC between 2000–2022, to analyze and compare eoCRC and average-onset colorectal cancer (aoCRC, disease diagnosed ≥50 years of age) patients. The frequency and spectrum of somatic mutations and PGVs in patients with eoCRC and aoCRC were evaluated and compared. Results: Among 11,006 participants in this study, 57% were male, 76% were white, and 80% had stage 4 disease. Within the total cohort, 2379 had eoCRC and 8627 had aoCRC. Among patients with eoCRC, 4.2% had a tumor with high microsatellite instability and/or deficient mismatch repair (MSI-H/dMMR) and 6.8% with aoCRC had an MSI-H/dMMR tumor (p < 0.001). The most frequent somatic mutations involved TP53, APC, and KRAS, with the most significant difference in BRAF, which was more frequently mutated in aoCRC (9.8% vs. 4.7%, p < 0.0001). In total, 1413 (59.4%) eoCRC and 4898 (56.8%) aoCRC patients had matched normal specimen (blood or saliva) sequencing and a PGV was identified in 6.9% of eoCRC and 5.0% of aoCRC patients. Conclusions: Somatic and germline mutation profiles were similar for eoCRC and aoCRC patients and may not adequately explain differences in tumor behavior and age of disease onset.
Outcomes of Minimally Invasive Nephrectomy Following Immune-Checkpoint Inhibitor Therapy: A Multicenter Propensity Score-Matched Analysis
Brönimann, Stephan, Gerald, Thomas , Helstrom, Emma, Deol, Ekamjit S. , Sobhani, Sina , Khene, Zine-Eddine, Thompson, R. Houston, Tachibana, Isamu , Khanna, Abhinav, Lee, Randall , Uzzo, Robert G. , Margulis, Vitaly , Djaladat, Hooman , Ghoreifi, Alireza , Ghoreifi, Alireza , Moghaddam, Farshad Sheybaee , Gill, Inderbir S. , Singla, Nirmish

Mayo Clinic

Journal of Endourology | February 27, 2025 | Volume: 39 | Issue: 4 | Pages: 399-404

10.1089/end.2024.0614 | PMID 40014477 Get It

Objectives: To report the outcomes of minimally invasive (MIS) nephrectomy following immune checkpoint inhibitor (ICI) therapy. Materials and Methods: This multicenter retrospective cohort study included consecutive patients who underwent nephrectomy following ICI therapy at five high-volume US academic centers between 2015 and 2023. Baseline clinical features and perioperative findings were recorded. After propensity-score matching (PSM), outcomes were compared between MIS and open nephrectomies. The primary outcome was 90-day complications, and secondary outcomes included length of hospital stay (LOS) and 90-day readmission. Results: A total of 158 patients were included, of whom 76 and 82 underwent MIS and open nephrectomies, respectively. The MIS procedures included robotic ( n = 56) and laparoscopic ( n = 20). A total of six (8%) patients converted to open. On multivariable analysis, patients with nonmetastatic vs metastatic renal-cell carcinoma (RCC) (hazard ratio [HR] 3.1, p = 0.01), those with smaller tumor size (HR 1.2 for each cm, p = 0.001), and no clinical evidence of inferior vena cava thrombus (HR 29, p = 0.002) were more likely to undergo the MIS approach compared with open approach. After PSM, including 56 MIS and 36 open nephrectomies, the MIS group compared with the open group had lower estimated blood loss (100 vs 460 mL, p < 0.001) and shorter LOS (2 vs 4 days, p < 0.001). Nevertheless, 90-day complications and readmissions were similar between the two groups. There were no 90-day mortality rates in either group. Conclusion: The MIS approach appears safe and offers more favorable perioperative outcomes compared with open surgery in properly selected patients with advanced RCC who are candidates for nephrectomy following ICI therapy.
Utility of MRI and CT in Sports Cardiology
Kumar, Vinayak , Domènech-Ximenos, Blanca , Francone, Marco , Allison, Thomas G. , Rajiah, Prabhakar , Kumar, Vinayak , Domenech-Ximenos, Blanca , Francone, Marco , Broncano, Jordi, Rajiah, Prabhakar , Broncano, Jordi

Mayo Clinic

RadioGraphics | February 27, 2025 | Volume: 45 | Issue: 3 | Pages: No page available

10.1148/rg.240045 | PMID 40014471 Get It

MRI and CT play an important role in sports cardiology, including preparticipation evaluation, distinguishing adaptive changes of athlete’s heart from pathologic entities, and evaluation following cardiovascular symptoms or adverse events.
The New CMS Measure of Excessive Radiation Dose or Inadequate Image Quality in CT: Issues and Ambiguities—Perspectives From an AAPM-Commissioned Panel
Wells, Jered R. , Christianson, Olav, Gingold, Eric L. , Jacobs, Jurgen, Boedeker, Kirsten , Ramírez-Giraldo, Juan Carlos , Yu, Lifeng , Gress, Dustin A. , Yu, Lifeng , McNitt‐Gray, Michael F. , Samei, Ehsan

Mayo Clinic

American Journal of Roentgenology | February 26, 2025 | Volume: 224 | Issue: 5 | Pages: No page available

10.2214/ajr.24.32458 | PMID 40008834 Get It